Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

MediVector Receives $135.5M DTRA Award

by Stephanie Lizotte
March 13, 2012
Biological and Chemical Defense Notable Contracts

MediVector, Inc., a privately held drug development company in Boston, is being awarded a $138,500,000 contract under a DoD Joint Project Manager Transformation Medical Technologies (JPM-TMT) initiative for advanced development of emerging infectious diseases medical countermeasures for FDA licensure.

Specifically, the company will further develop Favipiravir (T-705), a broad-spectrum therapeutic against multiple influenza viruses, including pandemic and drug resistant strains.

“Currently available medical countermeasures do not adequately protect the Joint Force,” said David E. Hough, Joint Project Manager of JPM-TMT.  “This drug shows promise that it can mitigate flu symptoms by interfering with the influenza replication process.  Our contract with MediVector addresses a capability gap in the protection of the Joint Forces.”

The Defense Threat Reduction Agency, Fort Belvoir, Va., is the contracting activity (HDTRA1-12-C-0031). The solicitation was issued for full and open competition and four proposals were received. Work is expected to be completed April 2016.

Tags: AntiviralsAwardsDefense Threat Reduction AgencyInfluenzaJPEO-CBRNDPandemic

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC